Drugs / AZD6912
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06115967 | Nov 2023 → Oct 2025 | rheumatoid arthritis | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD6912 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06115967 ↗ |
| Route | Subcutaneous | “AZD6912 will be administered as a single sub-cutaneous dose.” NCT06115967 ↗ |